LENZ (LENZ Therapeutics) Ending Cash Position: $24.21 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

LENZ LENZ Therapeutics Inc LENZ
12 GF Score
Price $5.05
! 3 Warning Signs
View Full Analysis

What is LENZ Therapeutics Ending Cash Position?

LENZ Therapeutics LENZ -3.26% 12 Ending Cash Position is $24.21 Mil as of Jun. 2026. GuruFocus rates LENZ with a GF Score™ of 12/100. The stock has 3 warning signs investors should review.

LENZ Therapeutics's Ending Cash Position for the quarter that ended in Jun. 2026 was $24.21 Mil.

LENZ Therapeutics's quarterly Ending Cash Position declined from Dec. 2025 ($25.18 Mil) to Mar. 2026 ($24.77 Mil) and declined from Mar. 2026 ($24.77 Mil) to Jun. 2026 ($24.21 Mil).

LENZ Therapeutics's annual Ending Cash Position declined from Dec. 2023 ($35.14 Mil) to Dec. 2024 ($20.27 Mil) but then increased from Dec. 2024 ($20.27 Mil) to Dec. 2025 ($25.18 Mil).

LENZ Therapeutics Ending Cash Position Related Terms

LENZ Therapeutics Ending Cash Position Historical Data

* Premium members only.

The historical data trend for LENZ Therapeutics's Ending Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

LENZ Therapeutics Ending Cash Position Chart

LENZ Therapeutics Annual Data
Trend Dec21 Dec22 Dec23 Dec24 Dec25
Ending Cash Position
18.31 44.44 35.14 20.27 25.18

LENZ Therapeutics Quarterly Data
Dec21 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Ending Cash Position Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 37.72 25.40 25.18 24.77 24.21
LENZ
12GF Score
LENZ Therapeutics Inc LENZ
Ending Cash Position is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

LENZ Therapeutics Ending Cash Position Calculation

Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. It is equal to the Beginning Cash Position plus the Net Change in Cash.

LENZ Therapeutics's Ending Cash Position for the fiscal year that ended in Dec. 2025 is calculated as

Ending Cash Position= Beginning Cash Position+Net Change in Cash
=20.272+4.907
=25.18

LENZ Therapeutics's Ending Cash Position for the quarter that ended in Jun. 2026 is calculated as

Ending Cash Position=Beginning Cash Position+Net Change in Cash
=24.772+-0.564
=24.21

Frequently Asked Questions Learn more about Ending Cash Position →
What does a Ending Cash Position of $24.21 Mil mean?
LENZ Therapeutics (LENZ) has a Ending Cash Position of $24.21 Mil as of Jun. 2026. Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. View historical data on LENZ Therapeutics and its competitors.
Is LENZ Therapeutics' Ending Cash Position too high?
LENZ Therapeutics' current Ending Cash Position is $24.21 Mil. Overall, LENZ Therapeutics has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does LENZ Therapeutics' Ending Cash Position compare to NGEN and ARMP?
LENZ Therapeutics' Ending Cash Position of $24.21 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Ending Cash Position for a Biotechnology company?
A good Ending Cash Position depends on the Biotechnology industry context. However, Ending Cash Position should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Ending Cash Position mean?
A high Ending Cash Position can signal that a stock is expensive relative to its fundamentals. Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. View historical data on LENZ Therapeutics and its competitors. LENZ Therapeutics's current Ending Cash Position is $24.21 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is LENZ Therapeutics stock overvalued right now?
LENZ Therapeutics (LENZ) has a current Ending Cash Position of $24.21 Mil. The current Ending Cash Position is $24.21 Mil. LENZ Therapeutics' overall GF Score™ is 12/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Ending Cash Position calculated?
Ending Cash Position is calculated from a company's financial statements. For LENZ Therapeutics (LENZ), the current Ending Cash Position is $24.21 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

LENZ Therapeutics Business Description

Address 201 Lomas Santa Fe Drive, Suite 300, Solana Beach, CA, USA, 92075
LENZ Therapeutics Inc is a late-stage biopharmaceutical company focused on developing and commercializing therapies to improve vision and developing ophthalmic pharmaceutical products. Its products VIZZ (aceclidine ophthalmic solution) 1.44% is a once-daily eye drop developed to restore clear near vision for up to 10 hours. VIZZ is powered by aceclidine, highlighted by its differentiated mechanism of action as a predominantly pupil-selective miotic that interacts with the iris, with minimal ciliary muscle stimulation.
12GF Score

Get the complete analysis for LENZ

Ending Cash Position is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$5.05
Price